Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Diabetic kidney disease (DKD) remains a leading cause of end-stage renal disease, with residual proteinuria driving progression despite optimized renin–angiotensin–aldosterone system (RAAS) blockade and sodium–glucose co-transporter-2 inhibitor (SGLT2i) therapy. Finerenone, a novel non-steroidal mineralocorticoid receptor antagonist (MRA), provides additional anti-inflammatory and antifibrotic benefit, yet real-world data on its concurrent use with SGLT2 inhibitors in South Asian populations are limited. This study evaluated the efficacy and safety of finerenone added to maximally tolerated dapagliflozin and telmisartan in patients with type 2 DKD.
This retrospective, single-centre study was conducted at a tertiary nephrology unit in Central India from January 2023 to June 2025. Forty-four adults with type 2 diabetes and CKD stages 2–4 (mean eGFR 46 ± 18 ml/min/1.73 m²) were included. All had persistent proteinuria despite optimised therapy and were maintained on dapagliflozin (10 mg/day) and telmisartan (40–80 mg/day) for ≥3 months before finerenone initiation. Finerenone was given at 10–20 mg once daily, adjusted for baseline eGFR and potassium. Clinical and biochemical parameters—urine protein-to-creatinine ratio (UPCR), eGFR, serum potassium, and blood pressure—were recorded at baseline and six months. Efficacy endpoints were the absolute and percentage change in UPCR and eGFR. Safety endpoints included hyperkalemia (≥5.5 mmol/L), urinary-tract infection, hypotension, and drug discontinuation. Paired t-tests were used for within-group comparisons.
Finerenone therapy produced a 46% mean reduction in proteinuria, with UPCR decreasing from 2.8 ± 1.4 to 1.5 ± 1.0 g/g (p < 0.001). Mean eGFR remained stable (46 → 45 ml/min; p = 0.47). Serum potassium rose slightly (4.3 → 4.6 mmol/L) but without clinically significant hyperkalemia or treatment discontinuation. Systolic and diastolic blood pressure decreased by 7 ± 3 and 4 ± 2 mmHg, respectively. Minor adverse events occurred in five patients (urinary tract infection in three, transient dizziness in two). No hospitalisations or deaths were reported during follow-up.
In patients with DKD already receiving maximally tolerated dapagliflozin and telmisartan, the addition of finerenone resulted in substantial proteinuria reduction and renal stability without increased adverse events. These findings highlight the complementary renoprotective mechanisms and safety of combined SGLT2–MRA–RAAS blockade in real-world South Asian practice.
